Patricia I Wang

Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.

M. Berger, R. Motzer, V. Reuter, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.

N. Socci, M. Berger, William Lee, 2015 .

Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis

J. Hsieh, E. Cheng, B. V. Van Tine, 2014, Cell Research.

Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets

N. Schultz, M. Berger, William Lee, 2016, Nature Communications.

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

N. Socci, A. Viale, M. Berger, 2017, European urology.

Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.

J. Cheville, V. Seshan, E. Papaemmanuil, 2017, JCI insight.

The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.

C. Leslie, N. Weinhold, William Lee, 2017, Cell reports.

Differential overall survival (OS) results in RECORD-3 study based on three distinct mRCC molecular subgroups classified by BAP1 and/or PBRM1 mutations.

M. Berger, William Lee, R. Motzer, 2016 .

MP47-09 MOLECULAR CHARACTERIZATION OF SARCOMATOID CLEAR CELL RENAL CELL CARCINOMA

William Lee, P. Russo, R. Motzer, 2015 .

A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features.

William Lee, R. Motzer, J. Chaim, 2015 .